NASDAQ:NEOS Neos Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Neos Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.64 -0.01 (-1.54 %) (As of 09/22/2020 12:00 AM ET) Add Compare Share Today's Range$0.63Now: $0.64▼$0.6950-Day Range$0.65MA: $0.69▼$0.7952-Week Range$0.60Now: $0.64▼$1.98Volume130,100 shsAverage Volume209,184 shsMarket Capitalization$31.75 millionP/E RatioN/ADividend YieldN/ABeta1.56 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Neos Therapeutics, Inc., a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate for treating of ADHD; Adzenys ER amphetamine to treat ADHD; and generic Tussionex hydrocodone and chlorpheniramine for cough and upper respiratory symptoms of a cold. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Neos Therapeutics. Previous Next 3.1 Community Rank Outperform VotesNeos Therapeutics has received 500 “outperform” votes. (Add your “outperform” vote.)Underperform VotesNeos Therapeutics has received 303 “underperform” votes. (Add your “underperform” vote.)Community SentimentNeos Therapeutics has received 62.27% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Neos Therapeutics and other stocks. Vote “Outperform” if you believe NEOS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NEOS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldNeos Therapeutics does not currently pay a dividend.Dividend GrowthNeos Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Neos Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.80% of the stock of Neos Therapeutics is held by insiders.Percentage Held by Institutions35.98% of the stock of Neos Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Neos Therapeutics are expected to grow in the coming year, from ($0.28) to ($0.04) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neos Therapeutics is -1.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Neos Therapeutics is -1.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 0.0Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.95 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NEOS Previous Symbol CUSIPN/A CIK1467652 Webwww.neostx.com Phone972-408-1300Debt Debt-to-Equity RatioN/A Current Ratio0.66 Quick Ratio0.52Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$64.65 million Price / Sales0.49 Cash FlowN/A Price / Cash FlowN/A Book Value($0.12) per share Price / Book-5.32Profitability EPS (Most Recent Fiscal Year)($0.34) Net Income$-16,900,000.00 Net Margins-30.56% Return on EquityN/A Return on Assets-22.66%Miscellaneous Employees215 Outstanding Shares49,755,000Market Cap$31.75 million Next Earnings Date11/13/2020 (Estimated) OptionableOptionable $0.64 -0.01 (-1.54 %) (As of 09/22/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive NEOS News and Ratings via Email Sign-up to receive the latest news and ratings for NEOS and its competitors with MarketBeat's FREE daily newsletter. Neos Therapeutics (NASDAQ:NEOS) Frequently Asked Questions How has Neos Therapeutics' stock price been impacted by Coronavirus (COVID-19)? Neos Therapeutics' stock was trading at $1.38 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, NEOS shares have decreased by 53.8% and is now trading at $0.6382. View which stocks have been most impacted by COVID-19. When is Neos Therapeutics' next earnings date? Neos Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, November 13th 2020. View our earnings forecast for Neos Therapeutics. How were Neos Therapeutics' earnings last quarter? Neos Therapeutics Inc (NASDAQ:NEOS) issued its earnings results on Monday, August, 10th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.13) by $0.02. The business earned $13.13 million during the quarter. View Neos Therapeutics' earnings history. Who are some of Neos Therapeutics' key competitors? Some companies that are related to Neos Therapeutics include Catabasis Pharmaceuticals (CATB), Pivot Pharmaceuticals (PVOTF), Evoke Pharma (EVOK), Tyme Technologies (TYME), Inflarx (IFRX), Equillium (EQ), Tonix Pharmaceuticals (TNXP), Zosano Pharma (ZSAN), Strongbridge Biopharma (SBBP), Rockwell Medical (RMTI), Lumos Pharma (LUMO), Corvus Pharmaceuticals (CRVS), Leap Therapeutics (LPTX), OASMIA PHARMACE/ADR (OASM) and Sierra Oncology (SRRA). View all competitors. What other stocks do shareholders of Neos Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neos Therapeutics investors own include SCYNEXIS (SCYX), Verastem (VSTM), TG Therapeutics (TGTX), TherapeuticsMD (TXMD), Exelixis (EXEL), Progenics Pharmaceuticals (PGNX), T2 Biosystems (TTOO), Amicus Therapeutics (FOLD), Rigel Pharmaceuticals (RIGL) and Trevena (TRVN). Who are Neos Therapeutics' key executives? Neos Therapeutics' management team includes the following people: Mr. Richard I. Eisenstadt, CFO, Treasurer & Corp. Sec. (Age 61)Mr. Gerald W. McLaughlin, CEO, Pres & Director (Age 51)Mr. John P. Limongelli, Sr. VP & Gen. Counsel (Age 49)Mr. Darren Heath, VP of SalesMr. Russ McMahen, Sr. VP of R&D When did Neos Therapeutics IPO? (NEOS) raised $60 million in an initial public offering on Thursday, July 23rd 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank, BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and JMP Securities was co-manager. What is Neos Therapeutics' stock symbol? Neos Therapeutics trades on the NASDAQ under the ticker symbol "NEOS." Who are Neos Therapeutics' major shareholders? Neos Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Goldman Sachs Group Inc. (5.32%), Jacobs Levy Equity Management Inc. (0.79%) and Bridgeway Capital Management Inc. (0.71%). Company insiders that own Neos Therapeutics stock include Alan L Heller, Gerald W Mclaughlin and Richard I Eisenstadt. View institutional ownership trends for Neos Therapeutics. Which institutional investors are buying Neos Therapeutics stock? NEOS stock was acquired by a variety of institutional investors in the last quarter, including Jacobs Levy Equity Management Inc., Bridgeway Capital Management Inc., and Goldman Sachs Group Inc.. Company insiders that have bought Neos Therapeutics stock in the last two years include Alan L Heller, Gerald W Mclaughlin, and Richard I Eisenstadt. View insider buying and selling activity for Neos Therapeutics. How do I buy shares of Neos Therapeutics? Shares of NEOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Neos Therapeutics' stock price today? One share of NEOS stock can currently be purchased for approximately $0.64. How big of a company is Neos Therapeutics? Neos Therapeutics has a market capitalization of $31.75 million and generates $64.65 million in revenue each year. The company earns $-16,900,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis. Neos Therapeutics employs 215 workers across the globe. What is Neos Therapeutics' official website? The official website for Neos Therapeutics is www.neostx.com. How can I contact Neos Therapeutics? Neos Therapeutics' mailing address is 2940 NORTH HIGHWAY 360, GRAND PRAIRIE TX, 75050. The company can be reached via phone at 972-408-1300 or via email at [email protected] This page was last updated on 9/23/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
